Stablizing An Enzyme By Forming A Mixture, An Adduct Or A Composition, Or Formation Of An Adduct Or Enzyme Conjugate Patents (Class 435/188)
-
Publication number: 20140256013Abstract: A process of producing a preparation of cell wall-degrading enzymes, comprising: expressing in plants or plant parts one or more than one heterologous cell wall-degrading enzyme; harvesting said plants or plant part containing said one or more than one cell wall-degrading enzyme; and storing the harvest as a silage. The silage may be used for degrading cell wall components of plant material or for producing a bioalcohol.Type: ApplicationFiled: October 17, 2012Publication date: September 11, 2014Applicant: NOMAD BIOSCIENCE GMBHInventors: Simone Hahn, Anatoli Giritch, Yuri Gleba
-
Publication number: 20140259215Abstract: The present invention provides, in one aspect, to a method for expressing DNase in a plant comprising growing a plant that has been transformed with a nucleic acid construct comprising a nucleic acid sequence encoding DNase under the control of a regulatory nucleotide sequence that regulates the transcription of said nucleic acid sequence in said plant.Type: ApplicationFiled: December 21, 2011Publication date: September 11, 2014Applicant: PHILIP MORRIS PRODUCTS S.A.Inventors: Karen Oishi, Manuel Peitsch
-
Publication number: 20140255378Abstract: The present invention provides PEGylated tyrosyl-tRNA synthetase (YRS) polypeptides, compositions comprising the same, and methods of using such polypeptides and compositions for treating or diagnosing a variety of conditions. The PEGylated YRS polypeptides of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic properties compared to non-PEGylated YRS polypeptides.Type: ApplicationFiled: August 8, 2012Publication date: September 11, 2014Applicant: aTyr Pharma, IncInventors: Jeffrey D. Watkins, Ying Ji Buechler, Chi-Fang Wu, Minh-Ha Do, Alain P. Vasserot, John D. Mendlein
-
Publication number: 20140255377Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.Type: ApplicationFiled: March 5, 2014Publication date: September 11, 2014Applicant: Vision Global Holdings Ltd.Inventors: Bing Lou WONG, Norman Fung Man WAI, Sui Yi KWOK, Yun Chung LEUNG
-
Publication number: 20140255309Abstract: A peptide for synthesizing silica and use thereof are provided. The peptide for synthesizing silica can polymerize silica from a silica precursor in an aqueous solution having conditions of normal temperature, normal pressure and near-neutral weak base. The peptide for synthesizing silica can form a self-assembled structure during silica synthesis, and thus can be used as various biomaterials such as a silica-based protein immobilizer, a biosensor, and a drug delivery system.Type: ApplicationFiled: October 2, 2012Publication date: September 11, 2014Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Seung Pil Pack, Mi Ran Ki
-
Publication number: 20140255411Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: March 18, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Zurit LEVINE, Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Shira WALACH, Shirley SAMEACH- GREENWALD, Tania PERGAM, Yaron KINAR
-
Publication number: 20140250942Abstract: A solution of sacrosidase in glycerol/water that is enzymatically stable indefinitely when maintained at about ?18° C. to ?22° C. is disclosed.Type: ApplicationFiled: March 6, 2013Publication date: September 11, 2014Applicant: QOL MEDICAL LLCInventors: Dayton T. Reardan, Brian L. Miller
-
Publication number: 20140255389Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.Type: ApplicationFiled: May 29, 2013Publication date: September 11, 2014Applicant: COMPUGEN LTD.Inventors: Anat COHEN-DAYAG, Merav BEIMAN, Liat DASSA, Marina BUBIS, Shirley SAMEACH- GREENWALD, Dalit LANDESMAN-MILO, Cynthia KOIFMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Zurit LEVINE, Avi ROSENBERG, Galit ROTMAN, Eve MONTIA, Amit NOVIK, Amir TOPORIK, Shira WALACH
-
Publication number: 20140248682Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.Type: ApplicationFiled: February 14, 2014Publication date: September 4, 2014Applicant: MEDIMMUNE, LLCInventors: Changshou GAO, Chaity CHAUDHURY, Xiaotao YAO
-
Publication number: 20140250548Abstract: Provided is a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding an NEMTOP6 polypeptide. Also provided are plants having modulated expression of a nucleic acid encoding an NEMTOP6 polypeptide, which plants have enhanced yield-related traits compared with control plants. Also provided are NEMTOP6-encoding nucleic acids, and constructs comprising the same, useful in enhancing yield-related traits in plants.Type: ApplicationFiled: April 13, 2012Publication date: September 4, 2014Applicant: BASF Plant Science Company GmbH Patents, Trademarks and LicensesInventors: Christophe Reuzeau, Steven Vandenabeele
-
Publication number: 20140242608Abstract: The present invention provides serum paraoxonase 1 protein as a biomarker useful for early diagnosis of lung cancer.Type: ApplicationFiled: February 28, 2013Publication date: August 28, 2014Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATIONInventor: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
-
Publication number: 20140242664Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR-Cas system.Type: ApplicationFiled: December 12, 2013Publication date: August 28, 2014Applicants: The Broad Institute, Inc., Massachusetts Institute of TechnologyInventors: Feng Zhang, Le Cong, Patrick Hsu, Fei Ran
-
Publication number: 20140242665Abstract: Fluorescent phenyl xanthene dyes are described that comprise any fluorescein, rhodamine or rhodol comprising a particular C9 phenyl ring. One or both of the ortho groups on the lower C9 phenyl ring is ortho substituted with a group selected from alkyl, heteroalkyl, alkoxy, halo, haloalkyl, amino, mercapto, alkylthio, cyano, isocyano, cyanato, mercaptocyanato, nitroso, nitro, azido, sulfeno, sulfinyl, and sulfino. In one embodiment, halo and/or hydroxy groups are used. Optimal dyes contain a lower C9 phenyl ring in which both ortho groups are the same and the lower ring exhibits some form a symmetry relative to an imaginary axis running from the phenyl rings point of attachment to the remainder of the xanthene dye through a point para to the point of attachment. The phenyl xanthene dyes may be activated. Furthermore, the phenyl xanthene dyes may be conjugated to one or more substances including other dyes.Type: ApplicationFiled: February 24, 2014Publication date: August 28, 2014Applicant: APPLIED BIOSYSTEMS, LLCInventors: Joe Y. LAM, Steven MENCHEN, Ruiming ZOU, Scott BENSON
-
Publication number: 20140242666Abstract: Disclosed are immunogenic conjugates and therapeutic compositions that include such immunogenic conjugates. Also disclosed are methods of treating and/or inhibiting an Shigella sonnei infection. The disclosed immunogenic conjugates have the general structure: Pr-Sr-O—N?C-Kdo-OS wherein Pr is a carrier protein, Sr is an optional spacer moiety, Kdo is an 3-deoxy-D-manno-octulosonic acid or a derivative thereof, and OS is an oligosaccharide or polysaccharide obtained from S. sonnei. In specific examples, the immunogenic conjugates include the core oligosaccharide obtained from S. sonnei having the structure: wherein R is between 1 and 10 disaccharide repeat units. In specific examples, the disaccharide repeat unit included in the immunogenic conjugate has the structure: ?-L-AltNAcA-3-?-FucNAc4N-4-.Type: ApplicationFiled: May 5, 2014Publication date: August 28, 2014Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Ser, National Research Council of CanadaInventors: John B. Robbins, Rachel Schneerson, Joanna Kubler-Kielb, Christopher P. Mocca, Evguenii Vinogradov
-
Publication number: 20140243258Abstract: Methods and compositions are presented for use in diagnostic, imaging or targeting of therapeutic agents to treat obesity/adiposity-associated disorders, where such as compositions and methods identify and use peptides to selectively target adipose tissue stromal cells in mammals, both in vitro and in vivo.Type: ApplicationFiled: March 30, 2012Publication date: August 28, 2014Applicant: The Board of Regents of the University of Texas SystemInventors: Mikhail G. Kolonin, Alexes Daquinag, Yan Zhang
-
Publication number: 20140242723Abstract: Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.Type: ApplicationFiled: February 28, 2014Publication date: August 28, 2014Applicant: IDEXX Laboratories, Inc.Inventors: Murthy V.S.N. Yerramilli, Mahalakshmi Yerramilli, Michael Atkinson, Kwok Kam Yeung
-
Publication number: 20140242056Abstract: There is provided a method of producing a stabilized catalase enzyme. In the method, a substrate is thoroughly mixed with phosphate borate and catalase, rinsed with water and the solids dried. The dried solid may be mixed with polyvinyl alcohol and dried for further stabilization. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Applicant: Kimberly-Clark Worldwide, Inc.Inventors: Bhalchandra M. Karandikar, Sunita J. Macwana, Zhongju Liu Zhao
-
Publication number: 20140242057Abstract: The present invention relates to B-domain truncated Factor VIII molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules.Type: ApplicationFiled: May 8, 2014Publication date: August 28, 2014Applicant: Novo Nordisk A/SInventors: Gert Bolt, Brian Berg Stidsen Vandahl, Lars Thim, Henning Ralf Stennicke, Thomas Dock Steenstrup, Shawn DeFrees
-
Publication number: 20140242618Abstract: The invention provides novel antibodies which specifically bind to the methylphenidate metabolite, ritalinic acid, enabling an immunoassay that can detect methyphenidate in biological samples for an extended period following its ingestion. The invention also describes novel conjugates and kits incorporating the antibodies.Type: ApplicationFiled: February 21, 2014Publication date: August 28, 2014Applicant: RANDOX LABORATORIES LIMITEDInventors: Philip Lowry, Elouard Benchikh, Ivan McConnell, Peter Fitzgerald
-
Publication number: 20140242699Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity and to edit or modify a target site in a genomic locus of interest to alter or improve the status of a disease or a condition.Type: ApplicationFiled: February 18, 2014Publication date: August 28, 2014Applicants: Massachusetts Institute of Technology, The Broad Institute Inc.Inventor: Feng ZHANG
-
Patent number: 8815553Abstract: The disclosure provides designer cellulosomes for efficient hydrolysis of cellulosic material and more particularly for the generating of ethanol.Type: GrantFiled: November 14, 2009Date of Patent: August 26, 2014Assignee: The Regents of the University of CaliforniaInventors: Wilfred Chen, Shen-Long Tsai
-
Publication number: 20140234336Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
-
Publication number: 20140234876Abstract: The present invention provides a hapten derivative and conjugate of a natural high intensity sweetener containing hydroxyl groups. The conjugate can be used to produce antibodies specific against the natural high intensity sweetener. The present invention further provides a kit and method for detecting and quantifying the natural high intensity sweetener in a sample.Type: ApplicationFiled: June 22, 2012Publication date: August 21, 2014Applicant: PURECIRCLE SDN BHDInventors: Jose Antonio Gabaldon Hernandez, Estrella Nunez Delicado, Rosa Puchades Pla, Angel Maquiera, Eva Maria Brun Sanchez, Avetik Markosyan
-
Publication number: 20140234365Abstract: The present invention relates to novel 2-hydroxyhippuric acid analogs, and methods for their synthesis and use. Such analogs are designed to provide a protected or functional moiety such as a free thiol (—SH) group or a protected thiol group, thereby providing a convenient linkage chemistry for coupling under mild conditions to a suitable group on a target protein, polypeptide, solid phase or detectable label.Type: ApplicationFiled: September 27, 2012Publication date: August 21, 2014Applicant: ALERE SAN DIEGO, INC.Inventor: Mariusz Banaszczyk
-
Publication number: 20140234209Abstract: The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific CDR sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein. More preferably, the antibodies or fragments also comprise specific constant region sequences, such as those associated with the nG1m1,2 or Km3 allotypes. The antibodies or fragments may bind to a human histone protein, such as H2B, H3 or H4. The antibodies or fragments are of use to treat a variety of diseases that may be associated with histones, such as autoimmune disease (e.g.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Applicant: Immunomedics, Inc.Inventors: Chien-Hsing Chang, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20140234221Abstract: Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use.Type: ApplicationFiled: April 2, 2014Publication date: August 21, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Hongtao Zhang, Xiaomin song, Ramachandran Murali, Masahide Tone
-
Publication number: 20140234853Abstract: Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation.Type: ApplicationFiled: December 16, 2013Publication date: August 21, 2014Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Peter VANDER HORN, Cheng-Yao CHEN, Guobin LUO, Michael PREVITE, Jamshid TEMIROV, Theo NIKIFOROV, Zhaohui ZHOU, Hongye SUN, Yufang WANG, Stefanie Yukiko NISHIMURA, Hongyi WANG, Marian PERIS, Barnett ROSENBLUM, Michael PHELAN
-
Publication number: 20140227723Abstract: Described herein are engineered microbe-targeting or microbe-binding molecules, kits comprising the same and uses thereof. Some particular embodiments of the microbe-targeting or microbe-binding molecules comprise a carbohydrate recognition domain of mannose-binding lectin, or a fragment thereof, linked to a portion of a Fc region. In some embodiments, the microbe-targeting molecules or microbe-binding molecules can be conjugated to a substrate, e.g., a magnetic microbead, forming a microbe-targeting substrate (e.g., a microbe-targeting magnetic microbead). Such microbe-targeting molecules and/or substrates and the kits comprising the same can bind and/or capture of a microbe and/or microbial matter thereof, and can thus be used in various applications, e.g., diagnosis and/or treatment of an infection caused by microbes such as sepsis in a subject or any environmental surface.Type: ApplicationFiled: July 18, 2012Publication date: August 14, 2014Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Donald E. Ingber, Michael Super, Jeffrey Charles Way, Mark J. Cartwright, Julia B. Berthet, Dinah R. Super, Martin M. Rottman, Alexander Watters
-
Publication number: 20140227759Abstract: An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type Oplophorus luciferase.Type: ApplicationFiled: January 21, 2014Publication date: August 14, 2014Applicant: PROMEGA CORPORATIONInventors: Brock Binkowski, Lance P. Encell, Mary Hall, Matthew B. Robers, Michael R. Slater, Keith V. Wood, Monika G. Wood
-
Publication number: 20140227717Abstract: Methods, compositions and kits are disclosed directed at posaconazole fragments, immunogens, signal generating moieties, antibodies that bind posaconazole and immunoassays for detection of posaconazole.Type: ApplicationFiled: February 10, 2014Publication date: August 14, 2014Inventors: Johnny Valdez, Soon J. Oh, Byung Sook Moon
-
Publication number: 20140227278Abstract: The invention provides a human signal peptide-containing proteins (SIGP) and polynucleotides which identify and encode SIGP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of SIGP.Type: ApplicationFiled: February 11, 2014Publication date: August 14, 2014Applicant: Incyte CorporationInventors: Preeti G. LAL, Jennifer L. Jackson, Neil C. Corley, Karl J. Guegler, Mariah R. Baughn, Susan K. Sather, Purvi Shah
-
Publication number: 20140227269Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.Type: ApplicationFiled: April 22, 2014Publication date: August 14, 2014Applicant: University of WashingtonInventors: Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
-
Publication number: 20140227323Abstract: An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.Type: ApplicationFiled: October 25, 2013Publication date: August 14, 2014Applicants: Ludwig Institute for Cancer, Institut PasteurInventors: Gilles DADAGLIO, Claude Leclerc, Daniel Ladant, Benoit Van Den Eynde, Sandra Morel, Cecil Bauche
-
Publication number: 20140227291Abstract: The present invention relates to amyloid-beta (A?) binding proteins. Antibodies of the invention have high affinity to A?(20-42) globulomer or any A? form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.Type: ApplicationFiled: August 12, 2011Publication date: August 14, 2014Inventors: Stefan Barghorn, Heinz Hillen, Andreas Striebinger, Simone Giasi, Ulrich Ebert, Chung-Ming Hsieh
-
Publication number: 20140230083Abstract: The present invention concerns new modular base-per-base specific nucleic acid binding domains (MBBBD) derived from newly identified proteins from the bacterial endosymbiont Burkholderia Rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.Type: ApplicationFiled: July 24, 2013Publication date: August 14, 2014Applicant: CELLECTISInventors: Claudia Bertonati, Philippe Duchateau, Alexandre Juillerat, George Silva, Julien Valton
-
Publication number: 20140220017Abstract: The present invention relates to complexes comprising (i) an immunoglobulin (Ig) binding moiety and (ii) a pharmaceutically active moiety, wherein the Ig binding moiety specifically binds to the constant domain 1 of the heavy chain (CH1) of an Ig molecule and their use for therapy and prophylaxis.Type: ApplicationFiled: September 24, 2012Publication date: August 7, 2014Inventors: Roland Kontermann, Felix Unverdorben, Meike Hutt
-
Publication number: 20140219983Abstract: The present invention relates to a method for suppressing or treating cancer, in particular to a method for suppressing or treating one or more of colorectal cancer, breast cancer, prostate cancer and/or lung cancer. The therapy employs use of a non-cytotoxic protease, which is targeted to a growth hormone-secreting cell such as to a pituitary cell. When so delivered, the protease is internalised and inhibits secretion/transmission of growth hormone from said cell. The present invention also relates to polypeptides and nucleic acids for use in said methods.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Syntaxin LimitedInventors: Frederic MADEC, Phil LECANE, Philip MARKS, Keith FOSTER
-
Publication number: 20140220656Abstract: Described herein are molecules, constructs and methods for the production and secretion of polypeptides of interest by host cells, preferably bacterial host cells, and more particularly gram positive bacteria. In particular, the present invention is related to a polynucleic acid encoding a fusion protein and to uses thereof for the secretion of heterologous or homologous polypeptides of interest by a bacterial host cell, preferably Clostridium bacteria. The present invention further relates to methods and constructs for the production and secretion of heterologous or homologous polypeptides of interest proteins by host cells using such polynucleic acids and fusion proteins.Type: ApplicationFiled: April 9, 2014Publication date: August 7, 2014Inventors: Henri-Pierre FIEROBE, Florence Mingardon, Angélique Chanal-Vial
-
Publication number: 20140220106Abstract: Disclosed herein are compositions and methods for and involving selectively targeting tumor lymphatics.Type: ApplicationFiled: September 13, 2013Publication date: August 7, 2014Applicants: The Regents of the University of California, Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Lianglin Zhang, Douglas Hanahan
-
Publication number: 20140219955Abstract: The instant invention provides soluble fusion protein complexes and IL-15 variants that have therapeutic and diagnostic use, and methods for making thesuch proteins. The instant invention additionally provides methods of stimulating or suppressing immune responses in a mammal using the fusion protein complexes and IL-15 variants of the invention.Type: ApplicationFiled: July 19, 2013Publication date: August 7, 2014Applicant: Altor BioScience CorporationInventors: Hing C. Wong, Peter Rhode, Xiaoyun Zhu, Kai-ping Han
-
Publication number: 20140212947Abstract: The present invention relates to a bioelectrode including a cross-linkable organometallic polymer, and to a method for manufacturing same, and more particularly, to an electrode in which a nanostructure of the organometallic polymer is controlled to be used in bio fuel cells, biosensors, and the like. The electrode according to the present invention includes an organometal and further includes a self-assembling block copolymer and enzyme, and provides usages in bio fuel cells and biosensors.Type: ApplicationFiled: January 16, 2012Publication date: July 31, 2014Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Moon Jeong Park, Joung Phil Lee
-
Publication number: 20140212896Abstract: All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression.Type: ApplicationFiled: March 28, 2014Publication date: July 31, 2014Applicant: Mor-NuTech, Inc.Inventors: D. James Morrè, Brandon Eugene Hostetler, James Jinpal Kim
-
Publication number: 20140212945Abstract: Disclosed are RNA targeting compounds, methods for using the subject RNA targeting compounds to treat myotonic dystrophy and other diseases are also disclosed.Type: ApplicationFiled: November 6, 2013Publication date: July 31, 2014Applicant: The Research Foundation for the State University of New YorkInventor: Matthew David Disney
-
Publication number: 20140212946Abstract: The present invention is directed toward the delivery of a toxic protein to pathogenic cells, particularly cancer cells. In preferred embodiments, the toxic protein is a ribonuclease that has been modified to make it toxic to target cells and that can be conjugated to a target cell-specific delivery vector, such as an antibody, for delivery to pathogenic cells.Type: ApplicationFiled: April 14, 2014Publication date: July 31, 2014Applicant: Quintessence Biosciences, Inc.Inventors: Laura E. Strong, Peter A. Leland, Thomas Burke
-
Publication number: 20140212403Abstract: The invention provides reagents and methods for enzyme replacement therapy using chemically modified species of human cystathionine ?-synthase (CBS) to treat homocystinuria and other related diseases and disorders.Type: ApplicationFiled: March 14, 2013Publication date: July 31, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF COLORADOInventors: Jan P KRAUS, Thomas MAJTAN, Erez BUBLIL
-
Patent number: 8790639Abstract: Peptidoglycan hydrolases are an effective new source of antimicrobials. A chimeric fusion protein of the Ply187 endopeptidase domain and LysK SH3b cell wall binding domain is a potent agent against Staphylococcus aureus in three functional assays.Type: GrantFiled: March 28, 2012Date of Patent: July 29, 2014Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: David M. Donovan, Jinzhe Mao
-
Publication number: 20140206061Abstract: The present invention relates to a bioactive carbon nanotube composite functionalized with a ?-sheet polypeptide block copolymer by combination self-assembly, which shows excellent water dispersion, and has biological activity so as to be used as stimulus-responsive and adaptable biomaterials or in the manufacture of CNT-based electronic biosensor devices. In addition, the bioactive carbon nanotube composite can be used as a composition for delivery of a biological active material into cells. Further, the application of the interaction between a ?-sheet peptide and a carbon-based hydrophobic material is expected to be useful for designing and developing an inhibitor for diseases caused by the abnormal folding of a protein and by biomacromolecular interactions (protein-protein, protein-DNA, and protein-RNA interactions etc).Type: ApplicationFiled: August 16, 2012Publication date: July 24, 2014Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Yong-Beom Lim, Woo-jin Jeong
-
Publication number: 20140205995Abstract: A method is disclosed for making a conjugate of two molecules using a hydrazide thiol linker. In a particular working embodiment, an Fc-specific antibody-enzyme conjugate is made using the method and demonstrated to provide exceptional staining sensitivity and specificity in immunohistochemical and in situ hybridization assays.Type: ApplicationFiled: February 14, 2014Publication date: July 24, 2014Applicant: Ventana Medical Systems, Inc.Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Casey A. Kernag, Jerome W. Kosmeder, Mark Lefever
-
Publication number: 20140206020Abstract: Methods, compositions and kits are disclosed directed at voriconazole derivatives, immunogens, signal generating moieties, antibodies that bind voriconazole and immunoassays for detection of voriconazole.Type: ApplicationFiled: January 17, 2014Publication date: July 24, 2014Inventors: Johnny Valdez, SOON J. OH, BYUNG SOOK MOON
-
Publication number: 20140199315Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (Negative Regulator). Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies.Type: ApplicationFiled: November 12, 2013Publication date: July 17, 2014Applicant: Biogen Idec MA Inc.Inventors: Sha MI, R. Blake Pepinsky, Zhaohui Shao, Christilyn Graff